Tinacure30 gm

Tinacure is a topical azole antifungal used to treat fungal infections of the skin (dermatophyte infections, commonly known as ringworm/tinea).

Established (FDA-approved) uses

• Interdigital tinea pedis (athlete's foot) caused by Trichophyton rubrum and Epidermophyton floccosum, in patients 12 years and older
• Tinea cruris (jock itch) caused by Trichophyton rubrum, in patients 12 years and older
• Tinea corporis (ringworm of the body) caused by Trichophyton rubrum, in patients 2 years and older

Other reported/off-label use

Tinacure has also been used off-label by clinicians for other localized superficial dermatophyte infections (e.g. tinea manuum) and, in some regions, for tinea versicolor and superficial candidiasis, based on its broad in-vitro antifungal spectrum; however, these uses are not FDA-approved indications and should only be used on a physician's advice.

Tinacure is for external (topical) use on the skin only.

Each gram of Luliconazole topical cream typically contains Luliconazole 1% w/w in a cream base.

Luliconazole may also be available as a topical solution or as a powder for compounding in certain markets; strength and available dosage forms can vary by manufacturer. Confirm the exact formulation on the product label/pack insert.

Tinacure is a synthetic imidazole-class antifungal agent developed for topical treatment of superficial dermatophyte skin infections. It is a newer-generation topical antifungal with fungicidal activity against common dermatophytes.

Tinacure is applied directly to the affected skin and is not intended for systemic (oral/injectable), ophthalmic, or intravaginal use.

Topical Antifungal Agent — Imidazole (Azole) class

Luliconazole is an azole antifungal that works by inhibiting the fungal enzyme lanosterol 14-α-demethylase (a cytochrome P450-dependent enzyme), which blocks the conversion of lanosterol to ergosterol.

Ergosterol is an essential component of the fungal cell membrane. By depleting ergosterol and allowing accumulation of toxic sterol intermediates, Luliconazole disrupts fungal cell membrane structure and function, producing a fungicidal (cell-killing) effect against dermatophytes such as Trichophyton rubrum and Epidermophyton floccosum.

Pharmacokinetics

• Systemic absorption through intact skin after topical application is minimal/low.
• Luliconazole is highly protein bound in plasma.
• Because systemic exposure is low, clinically significant systemic drug interactions or systemic adverse effects are uncommon with correct topical use.

For external use on the skin only.

• Clean and dry the affected area before applying Tinacure.
• Apply a thin layer that covers the affected skin plus a small margin of healthy surrounding skin, as directed.
• Rub in gently until the cream is absorbed.
• Avoid contact with the eyes, mouth, nose, and vagina/mucous membranes; if accidental contact occurs, rinse thoroughly with water.
• Do not cover the treated area with an occlusive (airtight) dressing unless a physician advises it.
• Wash hands after application (unless the hands are the treated area).

Tinacure is a weak inhibitor of the CYP2C19 liver enzyme in adults; this effect may approach a moderate level in some adolescent patients. Because systemic absorption of topically applied Tinacure is low, clinically significant drug interactions are uncommon, but caution and physician advice are recommended when Tinacure is used together with drugs that are sensitive CYP2C19 substrates (for example, certain proton pump inhibitors such as omeprazole, clopidogrel, diazepam, and some antidepressants), particularly with extensive or prolonged application.

No other clinically significant topical or systemic drug interactions are well established. Inform your physician or pharmacist about all medicines, including other topical products applied to the same area.

Tinacure is generally well tolerated when applied as directed. The most common adverse reactions, occurring in fewer than 1% of patients in clinical trials, are application-site reactions, generally mild in severity, including:

• Burning or stinging sensation at the application site
• Application-site irritation or redness
• Dryness or itching of the treated skin

Less commonly reported reactions (including from postmarketing experience) include contact dermatitis and, rarely, cellulitis at or near the application site.

Stop using Tinacure and consult a physician if signs of hypersensitivity (worsening redness, swelling, blistering, severe itching, or rash spreading beyond the application site) occur — see Precautions and Warnings.

Pregnancy

There are no adequate and well-controlled studies of Tinacure in pregnant women. Animal reproduction studies did not show adverse effects on the fetus at doses substantially higher than the maximum recommended human topical dose, but animal data do not always predict human response. As a relatively newer topical antifungal with limited human pregnancy data, Tinacure should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation

It is not known whether topically applied Tinacure passes into human breast milk. Because systemic absorption after topical application is low, risk to a breastfed infant is expected to be minimal, but data are limited. Caution is advised; avoid applying Tinacure directly to the breast/nipple area before breastfeeding, and consult a physician before use while breastfeeding.

Tinacure is for external (topical) skin use only.

• Not for ophthalmic, oral, or intravaginal use. Avoid contact with the eyes and other mucous membranes; if accidental contact occurs, rinse thoroughly with water and seek medical advice if irritation persists.
• Local irritation, burning, or redness may occur at the application site (see Side Effects). If irritation worsens or signs of hypersensitivity develop, discontinue Tinacure and consult a physician.
• Complete the full prescribed course of Tinacure exactly as directed, even if symptoms improve before the course is finished; stopping early can lead to incomplete clearance of the infection or recurrence, and inappropriate use of antifungals can contribute to reduced treatment response over time.
• If there is no improvement after the recommended treatment duration, or if the condition worsens, consult a physician — the diagnosis should be reconfirmed (for example, to rule out non-fungal skin conditions).
• As with any topical antifungal, avoid use on broken, infected, or actively weeping skin without medical advice.
• Because clinical experience with Tinacure is more limited than with older topical antifungals, use with additional caution in pregnancy, breastfeeding, and young children (see Pregnancy and Lactation, and Pediatric Uses).

Topical Tinacure is applied to a limited skin area, so systemic overdose is unlikely with normal use. Excessive or prolonged application beyond the prescribed area or duration may increase the risk of local irritation.

If Tinacure cream is accidentally ingested (swallowed) or a large amount is applied and systemic symptoms are suspected, seek immediate medical attention or contact a poison control center. Do not attempt specific home treatment for suspected overdose; medical evaluation is advised.

Store at room temperature, between 20°C and 25°C (68°F to 77°F); brief excursions to 15–30°C are permitted. Keep away from direct light, heat, and moisture. Do not freeze. Keep the tube tightly closed and out of the reach of children.

Renal impairment

No specific dose adjustment is established; systemic absorption after topical Tinacure use is minimal, so clinically relevant renal accumulation is not expected, but formal studies are lacking.

Hepatic impairment

No specific dose adjustment is established for topical use; formal studies in hepatic impairment have not been conducted.

Geriatric use

Clinical studies of Tinacure included patients 65 years and older, with no overall differences in safety or effectiveness observed compared with younger adults.

Pediatric use

See Pediatric Uses for age-specific approved indications and cautions.

Duration of Tinacure treatment depends on the indication being treated:

• Tinea pedis (athlete's foot): 2 weeks of once-daily application
• Tinea cruris (jock itch): 1 week of once-daily application
• Tinea corporis (ringworm): 1 week of once-daily application

The full course should be completed as prescribed even if the skin appears to improve sooner. If symptoms persist after the course is finished, consult a physician rather than extending treatment on your own.

Antifungals > Azole (imidazole-derivative) antifungals > Topical antifungal creams

Luliconazole inhibits fungal lanosterol 14-α-demethylase, an enzyme required to convert lanosterol into ergosterol. This blocks ergosterol synthesis and causes toxic sterol intermediates to build up in the fungal cell membrane, disrupting membrane integrity and function. This mechanism is fungicidal against common dermatophytes such as Trichophyton rubrum and Epidermophyton floccosum (see Pharmacology for details).

Approved pediatric use of Tinacure is age- and indication-specific:

• Tinea corporis: safety and effectiveness have been established in children 2 years of age and older.
• Tinea pedis and tinea cruris: safety and effectiveness have been established only in patients 12 years of age and older; safety and efficacy in children below 12 years for these indications have not been established.

Tinacure should not be used in infants or younger children outside these approved ranges except under direct physician guidance, given more limited pediatric safety data compared with older topical antifungals. Use in children should always be supervised by an adult to avoid accidental contact with the eyes or mouth.